Готові списки джерел за темами / Breast Cancer Patients Malaysia

Добірка наукової літератури з теми "Breast Cancer Patients Malaysia"

Автор: Grafiati
Опубліковано: 10 грудня 2022
Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Breast Cancer Patients Malaysia".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Breast Cancer Patients Malaysia"

1

Muhamad, Mazanah, Sharan Merriam, and Norhasmilia Suhami. "Why Breast Cancer Patients Seek Traditional Healers." International Journal of Breast Cancer 2012 (2012): 1–9. http://dx.doi.org/10.1155/2012/689168.

Повний текст джерела
Анотація:
Traditional healing is a common practice in low and middle income countries such as Malaysia. Eighty percent of Malaysians consult traditional healers or “bomoh” at some time in their life for health-related issues. The purpose of our study was to explore why breast cancer patients visit traditional healers. This is a qualitative study utilizing in-depth interviews with 11 cancer survivors who sought both traditional and Western medicine. The findings revealed the following reasons for which patients seek traditional healers: (1) recommendation from family and friends, (2) sanction from family, (3) perceived benefit and compatibility, (4) healer credibility, and (5) reservation with Western medicine and system delay. These factors work together and are strongly influenced by the Malaysian cultural context. The issue with the Western health system is common in a developing country with limited health facilities.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Amini, Farahnaz, Wong Fu Hou, Edmond Ng Siah Chye, Roslina Omar, Shafinaz Mohd Rejab, Izyan Wajiha Mohd Noor, and Baizurah Mohd. Hussain. "MUTATION PROFILE OF BREAST CANCER IN MALAYSIAN PATIENTS." Journal of Health and Translational Medicine 24, no. 1 (March 5, 2021): 37–44. http://dx.doi.org/10.22452/jummec.vol24no1.6.

Повний текст джерела
Анотація:
Background: Breast cancer (BC) is the most common cancer in women globally. In low- and middle-income countries, the use of appropriate breast cancer genetics services for screening and personalized treatments is severely lacking. This review is aimed to assess and summarize the reported mutation profiles of Malaysian BC patients. Methods: A literature search was performed in PubMed and Google Scholar from 2002 to 2019 using a set of keywords and MESH terms. Results: Data from 14 eligible studies are presented here. A total of 28 genes were studied in Malaysian BC patients in which 445 genetic alterations (229 deleterious, 209 variants with unknown clinical significance (VUC), and seven protective variants) have been reported, with 73 being novel (16% novel). The frequency ranged from 0.2% to 76% for VUC and 2.1 to 15% for deleterious variations. Only BRCA1, BRCA2, PALB2, APOBEC3B, and P53 have been associated with BC risk in Malaysian patients. Nine of these studies were conducted using the overlapped source of patients, which may limit the generalizability of the findings to the whole population of Malaysia. Conclusion: Information on the genetic basis of BC in the Malaysian population is scant. Multidisciplinary efforts with appropriate sample selection techniques and study design with multicenter collaboration are needed to address this issue. Out of thirteen high- and moderated-penetrance pathogenic mutations for BC, only five have been linked to Malaysians’ BC susceptibility. The findings from this review is valuable for decision-makers, researchers, and physicians, to enhance the research plans and utility of genetic services for screening and prevention.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Shaharudin, Soraya Hanie, Suhaina Sulaiman, Mohd Razif Shahril, Nor Aina Emran, and Sharifah Noor Akmal. "Dietary Changes Among Breast Cancer Patients in Malaysia." Cancer Nursing 36, no. 2 (2013): 131–38. http://dx.doi.org/10.1097/ncc.0b013e31824062d1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Nair, Viji, Viji Dina Nazri, Angela Lau, Rozita Hashim, Clare Ratnasingham, and Murallitharan Munisamy. "Impact of a Targeted Free Mammography Screening Program for Underprivileged Women in Malaysia." Journal of Global Oncology 4, Supplement 3 (October 2018): 28s. http://dx.doi.org/10.1200/jgo.18.10320.

Повний текст джерела
Анотація:
Purpose Breast cancer remains the most prevalent cancer among Malaysians today. Almost two thirds of patients are diagnosed in the late stages of disease, stage III to IV, with poorer outcomes. In addition, evidence has also revealed that most of patients who present in these late stages are those from poorer socioeconomic backgrounds. Women from underprivileged backgrounds have been found to have poorer health-seeking behavior, especially in terms of screening for cancer. This is for a number of reasons, such as affordability, distance to health centers, and other socioeconomic factors, which have a large impact, as Malaysia only offers opportunistic screening for breast cancer and not for free. A specific program to provide free mammography screening targeted toward underprivileged Malaysian women was planned and implemented with the aim of improving access to screening and increasing the rate of screening among this specific group of women. Methods Funding for the program was obtained from successful negotiation with a large Malaysian life insurance carrier. To ensure geographic equity, screening services were strategically purchased from 15 hospitals that were spread out across Malaysia. We also built partnerships with various nongovernmental organizations working in the social arena servicing underprivileged groups to reach these groups specifically. The nongovernmental organizations co-organized awareness programs and screening days, together with the National Cancer Society Malaysia, with additional incentivization that included subsidizing transport to mammography centers. Results A total of 5,000 underprivileged women from different geographic localities and ethnicities were screened across Malaysia. Of these, 62% received a mammogram for the first time in their lives, whereas 21% received their first repeat mammogram in more than 3 years. Conclusion A targeted screening program that incorporated a multipronged approach strategy was successful at increasing access to breast cancer screening for underprivileged Malaysian women. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc . Murallitharan Munisamy Employment: National Cancer Society of Malaysia Stock or Other Ownership: MMPKV Sdn Bhd–operator of Malaysian Primary Care Clinics
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Lim, Z. Y., N. Rajaram, C. V. Song, R. Kaur, N. A. Mohd Taib, M. Muhamad, W. L. Ong, et al. "Patient-Reported Outcome Measures Among Breast Cancer Survivors in Malaysia: A Comparative Study With Patients From High-Income Countries." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 103s. http://dx.doi.org/10.1200/jgo.18.75100.

Повний текст джерела
Анотація:
Background: Patient-reported outcome measures (PROMs) are essential for identifying how patients perceive the outcomes of their cancer treatment, and is the ultimate success of cancer care. Although a growing number of studies have focused on PROMs in high income countries (HICs), outcomes relevant to patients in developing countries are less understood. Furthermore, the lack of standardization in PROMs makes it difficult to interpret these data for research or quality monitoring. Aim: In this study, we compared the results of PROM measures between patients in Malaysia, a middle income country, and those in HICs, using standard PROMs questionnaires. We also explored the differences in perceived importance of patient reported outcomes within the multiracial Malaysian cohort. Methods: Breast cancer patients (n=1063) were recruited in hospitals serving suburban areas of Malaysia. Of these, 969 patients were eligible for analysis. The surveys were conducted through face-to-face interviews (68%) or were self-administered (30%). An outcome was considered important if it was scored between 7-9 on a 9-point Likert scale. We compared PROMs scores between Malaysian patients and data previously collected from patients in HICs using logistic regression models, adjusting for demographic and clinical characteristics. A two-step cluster analysis was conducted to explore differences in the perceived importance of PROMs between clusters of Malaysian patients. Results: Compared with 1777 patients from HICs, Malaysian patients were less likely to rate overall and recurrence free survival, as well as emotional, cognitive, social and sexual functioning as very important outcomes. Interestingly, more Malaysian women reported that pain (50% vs. 39%), breast symptoms (51% vs. 35%), and major complications (60% vs. 44%) were very important outcomes ( P < 0.001). Compared with young, married Malaysian women, the cluster of older married women (mean age of 57 vs. 52), who were less likely to have received breast reconstructive surgery (8.6% vs. 16.8%), was more likely to rate sexual functioning (32.8% vs. 25.0%, P = 0.036), body image (63.9% vs. 42.4%, P < 0.001), and satisfaction with the breast (50.7% vs. 37.0%, P = 0.011) as very important outcomes. Conclusion: The differences in breast cancer patient needs between and within populations should be considered carefully to better clinician-patient relationship, patient care and satisfaction and assess the outcomes of our cancer care. Future research is needed to find suitable targeted interventions to identify and address the diverse needs of breast cancer patients in low and middle income countries.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Ganesh, Sri, Munn-Sann Lye, and Fen Nee Lau. "Quality of Life among Breast Cancer Patients In Malaysia." Asian Pacific Journal of Cancer Prevention 17, no. 4 (June 1, 2016): 1677–84. http://dx.doi.org/10.7314/apjcp.2016.17.4.1677.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Nies, Yong Hui, Farida Islahudin, Wei Wen Chong, Norlia Abdullah, Fuad Ismail, Ros Suzanna Ahmad Bustamam, Yoke Fui Wong, Saladina Jaszle, and Noraida Mohamed Shah. "Treatment decision-making among breast cancer patients in Malaysia." Patient Preference and Adherence Volume 11 (October 2017): 1767–77. http://dx.doi.org/10.2147/ppa.s143611.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Fatimah Sham, Normala Salim, Nor Hafizatul Akma Shohor, Siti Fatimah Zahra Mohd Anuar, Ain Aqiela Azamuddin, and Norziah Aman. "QUALITY OF LIFE AND SOCIAL SUPPORT AMONG BREAST CANCER PATIENTS IN MALAYSIA." Malaysian Journal of Public Health Medicine 22, no. 1 (April 28, 2022): 154–63. http://dx.doi.org/10.37268/mjphm/vol.22/no.1/art.1077.

Повний текст джерела
Анотація:
Cancer incidence and mortality are rapidly growing worldwide, and Breast Cancer is one of the leading causes of death among women in Malaysia. Social support is an important aspect of the Quality of Life (QoL) as it affects the psychological well-being and health of the patients. The aim of this study is to assess the quality of life and relationship of QoL with social support among female patients with diagnosed Breast Cancer. This is a cross-sectional study involving 259 female patients with diagnosed Breast Cancer from the outpatient unit of the National Cancer Institute, Malaysia. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and its breast-specific module (QLQ-BR23) measured QoL and social support by using Perceived Social Support (MPSS) questionnaires. The data was analysed using SPSS version 25.0. The result of this study found that women with Breast Cancer in Malaysia had an excellent global quality of life in which they were able to achieve the highest score in their role and physical function. The result also showed a high rate of social support especially supports from family. There was a positive relationship between QoL and social support (rs: 0.25) generally with a p-value less than 0.05. Therefore, effective measures need to be taken and implemented concerning improving the QoL of Breast Cancer patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Mujar, Noor Mastura Mohd, Maznah Dahlui, and Nur Aishah Taib. "Presentation, Diagnosis, and Treatment Among Patients With Breast Cancer in Malaysia." Journal of Global Oncology 4, Supplement 3 (October 2018): 25s. http://dx.doi.org/10.1200/jgo.18.10280.

Повний текст джерела
Анотація:
Purpose Breast cancer is the most common form of cancer among women in Malaysia. Although there is a scarcity of data on the relation between delays and survival, it is generally accepted that optimum outcomes are dependent on the early detection and adherence to treatment. This study was conducted to evaluate the time intervals and associated factors with delays in presentation, diagnosis, and treatment among patients with breast cancer who attended public hospitals in Malaysia. Methods A retrospective cohort study was conducted in six public hospitals involving all patients with newly diagnosed breast cancer from January 1, 2012, to December 31, 2012. Data were collected through review of medical records and interviews using a structured questionnaire. Presentation delay was defined as time taken from the discovery of symptoms to the first presentation at primary care of more than 3 months. Diagnosis delay was defined as time taken from the first presentation to diagnosis disclosure of more than 1 month, and treatment delay was defined as time taken from diagnosis disclosure to initial treatment of more than 1 month. We used univariable logistic regression and multiple logistic regressions for analysis. A total of 340 patients with breast cancer were included in the study. Median times for presentation, diagnosis, and treatment were 2.4 months, 26 days, and 21 days, respectively. The presentation delay rate was 35%, and the factors associated with it were location (Kelantan: odds ratio [OR], 4.78) and use of complementary and alternative medicine (OR, 1.67). The diagnosis delay rate was 41.8%, and the factors associated with it were symptoms without lump (OR, 1.98), undergoing two or more biopsies (OR, 3.02), and surgical biopsy (OR, 2.56). Meanwhile, the treatment delay rate was 35.3%, and the factors associated with it were location (Johor: OR, 4.95; Kelantan: OR, 6.68; and Sarawak: OR, 3.88) and those diagnosed at other hospitals (OR, 2.18). Results Delays in presentation, diagnosis, and treatment were high among patients with breast cancer who attended public hospitals in Malaysia. Factors that influenced delays were locality, socio-culture, patients, and health systems. Mutual collaboration involving patients and health care sectors and a comprehensive intervention study are suggested to improve the quality of breast cancer care in Malaysia. Conclusion Delays in presentation, diagnosis, and treatment were high among patients with breast cancer who attended public hospitals in Malaysia. Factors that influenced delays were locality, socio-culture, patients, and health systems. Mutual collaboration involving patients and health care sectors and a comprehensive intervention study are suggested to improve the quality of breast cancer care in Malaysia. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc . No COIs from the authors.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Bustamam, Ros Suzanna Ahmad, Yu Kong Leong, Flora Li Tze Chong, Florence Wong Yoke Fui, Yew-Teik Cheong, and Goh Kenny. "A Retrospective, Observational Study to Determine the Patient and Tumor Characteristics of HER2-Positive Breast Cancer Patients Treated at Five Main Public Cancer Centers in Malaysia." Asian Journal of Oncology 6, no. 01 (January 2020): 10–19. http://dx.doi.org/10.1055/s-0040-1708108.

Повний текст джерела
Анотація:
Abstract Introduction Human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer is a high-risk subtype with poor prognosis. The incidence of HER2 expressing tumors is high in Malaysia; however, there is limited information on the characteristics of these tumors. Therefore, we sought to collect the patient and tumor characteristics of HER2+ breast cancer cases at five centers in Malaysia. Patients and Methods A retrospective review was conducted of the data from charts of patients diagnosed with HER2+ breast cancer between January 2014 and December 2015 at Hospital Kuala Lumpur, Institute Kanser Negara, Hospital Pulau Pinang, Hospital Besar Sarawak, and Hospital Likas in Malaysia. Results Of the 1,519 screened patient’ charts, 396 were included for the analysis. The average age of HER2+ breast cancer cases at diagnosis was 51.07 years. A high percentage of cases presented at an advanced stage (38.89 and 12.12% with stage 3 and 4, respectively). About 58.84% of patients were categorized as “high-risk,” with one or more lymph node involvement. Close to half (47.98%) of cases presented with T2 stage tumors, and infiltrating ductal carcinomas were reported in 85.35% of tumors. The most common immunohistochemical subtype was estrogen receptor (ER)+/progesterone receptor (PR)+/HER2+ (47.47%), followed by ER–/PR–/HER2+ (37.12%). Conclusion HER2 overexpressing tumors represent an aggressive subtype in Malaysia with large tumor size, high tumor grade, and lymph node involvement. Early diagnosis and management of these tumors may help improve the survival rates. Future studies should help elucidate the treatment patterns and outcomes in HER2+ breast cancer patients in Malaysia.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Breast Cancer Patients Malaysia"

1

Dasch, Kimberly B. "Affective differentiation in breast cancer patients." Access to citation, abstract and download form provided by ProQuest Information and Learning Company; downloadable PDF file, 70 p, 2009. http://proquest.umi.com/pqdweb?did=1885670961&sid=7&Fmt=2&clientId=8331&RQT=309&VName=PQD.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Lagergren, Jakob. "Immediate breast reconstruction with implants in breast cancer patients /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-230-9/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Yeung, Shuk-chong Rene. "Self-evaluation of coping resources of cancer patients /." Hong Kong : University of Hong Kong, 1999. http://sunzi.lib.hku.hk/hkuto/record.jsp?B22330914.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Cheng, Wing-ming Edward. "Emotional well-being in Chinese lung cancer patients." Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B3197157X.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Wolfman, Jessica Heather Kloss Jacqueline D. "Cancer specific stress and insomnia severity among breast cancer patients /." Philadelphia, Pa. : Drexel University, 2009. http://hdl.handle.net/1860/3024.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Daniels, Tasneem. "Bi-rads final assessment categories in breast cancer patients." Thesis, Cape Peninsula University of Technology, 2019. http://hdl.handle.net/20.500.11838/2969.

Повний текст джерела
Анотація:
Thesis (MSc (Radiography))--Cape Peninsula University of Technology, 2019
INTRODUCTION: The Breast Imaging Reporting and Data System (BI-RADS) was developed by the American College of Radiology (ACR). The BI-RADS is an internationally accepted method of assessing and reporting on mammograms and breast ultrasound images. The BI-RADS consists of a lexicon (descriptors) and assessment categories. The ACR aimed to standardise mammography reporting and placing the findings in the appropriate assessment category. The aim of this study was to establish the accuracy of the BI-RADS assessment categories for mammography and breast ultrasound images in women diagnosed with breast cancer. METHOD: Data were retrieved from 77 patients who were diagnosed with breast cancer from 1 January 2013 to 31 December 2014. Seven did not meet the inclusion criteria and were excluded. The study sample size was 70 (n=70) patients. All mammography reports included a BI-RADS assessment category of all patients diagnosed with breast cancer within the study period. These reports were analysed and compared with histopathology results. The BI-RADS assessment category and descriptors were collected from the mammogram reports; the histopathology report indicated the type of breast cancer. All reports were obtained from the patients' folders at the research site. In addition, questionnaires were distributed among radiologists to assess whether their experience and training had an influence on the accuracy of reporting in the BI-RADS assessment categories. Descriptive and inferential statistical analysis was used for data analysis. RESULTS: The most common malignancy diagnosed was invasive ductal carcinoma with a total of 70% (n=54), followed by ductal carcinoma in situ with 10.4% (n=8) and invasive lobular carcinoma with 9.1% (n=7). The histology results confirmed breast cancer for all BI-RADS 4 and 5 assessment categories. The mammogram was able to detect 93.5% of abnormalities and breast ultrasound 84.4% of abnormalities in this study sample. Breast ultrasound was used as an adjunct to mammography and hence an overall combined diagnostic rate was 100%. Mammography descriptors: The more common malignancy findings were spiculated mass margin, 35.1% (n=27). Ultrasound descriptors: The more common malignancy findings were hypoechoic echo pattern, 55.8% (n=43). There was no significant association (p=0.152) between the radiologists' years of experience and BI-RADS 3, 4 and 5 assessment category reporting. Of the 15 responses, 67% agreed that the BI-RADS standardises breast imaging reporting and reduces confusion, 33% agreed that the BI-RADS allows better communication between radiologists and referring physicians, and 40% agreed that the BI-RADS clarifies further management for patients by helping to stratify risk management. CONCLUSION: The outcome of this study indicated that the use of BI-RADS assessment categories is useful for predicting the likelihood of malignancy when used correctly. The outcome of BI-RADS 4 and BI-RADS 5 had a positive predictive value of 100%, which corresponded well with histology results. The descriptor findings suggested that spiculated mass margins, irregular-shaped masses, hypoechoic echo pattern and posterior shadowing were high predictors of malignancy and warranted a placement in the BI-RADS 5 assessment category.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Alburai'Si, Kholoud Mubarak. "Stratification of breast cancer patients : a proteomic approach." Thesis, King's College London (University of London), 2016. https://kclpure.kcl.ac.uk/portal/en/theses/stratification-of-breast-cancer-patients(a8102723-9f21-4495-8401-d3e8ce503968).html.

Повний текст джерела
Анотація:
Breast cancer represents a heterogeneous collection of different diseases characterized by different pathological and biological features, clinical presentation, clinical behaviour, response to treatment and outcome. In current practice, pathological diagnosis and classification of breast cancer is based mainly on well-established traditional morphologic features. However, morphological features alone do not adequately reveal the molecular heterogeneity and complexity of breast cancer. Still, there are relatively few biomarkers widely used in prognostication in invasive breast cancer and in predicting response to targeted therapies, and even fewer of value in the clinical management of the pre-invasive disease of ductal carcinoma in situ (DCIS). There is therefore an unmet need for biomarkers for better classification, better prediction of prognosis and of prediction of response to therapy for both invasive breast carcinoma and DCIS. The co-expression of a HER2/HER3 combination results in more aggressive tumour growth and is associated with endocrine and chemotherapy resistance, driven not simply by receptor expression but also by signalling via the receptors dimers. Therefore, methods which directly query signalling pathway activation in breast cancer specimens are anticipated to provide important insights into the molecular ‘‘logic’’ that distinguishes cancer from normal tissues and potentially to have an important impact on personalized intervention strategies. The aim of this thesis has been directed at evaluating candidate biomarkers in breast cancer. This has been targeted at examining attributes associated with known functional properties of candidate drivers of disease or resistance to treatment rather than those traditionally based on altered expression of these biomarkers. Specifically, the work was directed at the HER1-3 members of the EGFR family of growth factor receptor in breast cancer. In this project I have in part developed, tested and evaluated two methods, which have the ability to detect protein-protein complexes at a single molecule level and thus allow the study of signalling pathways in situ. The first method is an in-house coincidence detection technology created from two recombinant fusion proteins and the second is a commercially available proximity ligation assay (PLA) method. Both approaches were able to detect the target proteins with high sensitivity and specificity, however the proximity ligation assay was subsequently used here to assess the protein complexes and activation status of the EGFR family in breast cancer patient’s samples. The patient study cohort is derived from a consecutive series of approximately 293 cases of primary operable invasive breast cancers obtained from the Guy’s and St Thomas (King’s Health Partner’s) Breast Cancer Biobank archive presenting between 1990 and 1992. In these cases, 9 different biomarkers were studied for HER family expression level, dimer expression and activation status using proximity ligation assays (PLAs). The relationship between HER activation status, dimer expression and relapse free survival (RFS) was investigated and stratified multivariate regression analysis identified factors influencing patient prognosis. In conclusion, PLA successfully and reproducibly detected HER protein complexes and phosphorylation in vivo. A significant association was identified between high levels of phosphorylated HER2 and reduced recurrence-free survival (RFS) in invasive lobular carcinoma (p = 0.04, HR 0.99, 95% CI: 0.997-1.002). High levels of HER1/HER3 dimers were associated with reduced RFS in T1 (<2cm) breast cancer patients, (p = 0.02, HR 1.84, 95% CI: 1.08-3.13). Similarly, high levels of HER1/HER3 and HER2/HER3 dimers were associated with reduced RFS in breast cancer patients with N1 nodal status (p <0.0001, HR 1.84, 95% CI: 0.58-1.93) and (p <0.0001, HR 0.64, 95% CI: 0.45-0.90) respectively). Work in this thesis demonstrates that in situ detection of HER protein complexes and activation status can be monitored robustly and with specificity in clinical specimens, providing novel prognostic information. This technique was also applied successfully to assess the HER family in a smaller number of DCIS cases. This novel technique and approach could potentially be applied for patient stratification and assist in the selection of more individualized treatment options according to tumour molecular characteristics.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Molenaar, Jacobus. "Treatment decision support for early breast cancer patients." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2004. http://dare.uva.nl/document/77496.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Blackwelder, Reid B. "Integrative Approaches to Treating Patients with Breast Cancer." Digital Commons @ East Tennessee State University, 2007. https://dc.etsu.edu/etsu-works/6985.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Jansen, Catherine E. "Cognitive function in breast cancer patients undergoing chemotherapy." Diss., Search in ProQuest Dissertations & Theses. UC Only, 2007. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:3261235.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Breast Cancer Patients Malaysia"

1

Ellis, Alda. Beyond breast cancer. Eugene, Or: Harvest House, 2002.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Colmore, Perry. Living with breast cancer. Andover, Mass: Andover Townsman, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Breast cancer: Taking control. Sydney, Australia: Boycare Publishing, 2010.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Chart, Pamela. Breast cancer: A guide for patients. Toronto: Prospero Books, 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Kneece, Judy C. Your breast cancer treatment handbook. 2nd ed. Columbia, South Carolina: EduCare Pub., 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Canadian Breast Cancer Research Initiative. Canadian Breast Cancer Initiative guidelines for the care & treatment of breast cancer. [Ottawa]: Health Canada, Canadian Breast Cancer Initiative, 1998.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Kneece, Judy C. Breast cancer treatment handbook: Understanding the disease, treatments, emotions and recovery from breast cancer. 7th ed. North Charleston, SC: EduCare, 2009.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Kneece, Judy C. Breast cancer treatment handbook: Understanding the disease, treatments, emotions and recovery from breast cancer. 8th ed. North Charleston, SC: EduCare, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Project, The Healing. Voices of Breast Cancer. Chicago: LaChance Publishing, 2008.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Olmstead, Lois. Breast cancer and me: A humorous, hope-filled story of a breast cancer survivor. Camp Hill, Pa: Christian Publications, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Breast Cancer Patients Malaysia"

1

Tee, Jing Ying, and Suliadi F. Sufahani. "Menu Planning and Scheduling for Vegetarian Breast Cancer Patients in Malaysia Using Optimization Approaches." In Proceedings of the Third International Conference on Trends in Computational and Cognitive Engineering, 203–12. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7597-3_16.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Truong, Anne N. "Rehabilitation of Patients with Breast Cancer." In Breast Cancer, 430–51. New York, NY: Springer New York, 2001. http://dx.doi.org/10.1007/978-0-387-21842-7_16.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Gianni, Lorenzo, Alessandra Affatato, and Davide Tassinari. "Follow-Up of Patients with Breast Cancer." In Breast Cancer, 769–78. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48848-6_65.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Ramirez, Pedro T., and Ralph S. Freedman. "Gynecologic Problems in Patients with Breast Cancer." In Breast Cancer, 382–405. New York, NY: Springer New York, 2001. http://dx.doi.org/10.1007/978-0-387-21842-7_14.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Fornage, Bruno D. "Role of Sonography in Patients with Breast Cancer." In Breast Cancer, 18–52. New York, NY: Springer New York, 1999. http://dx.doi.org/10.1007/978-1-4612-2146-3_3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Gwyn, Karin M., and Richard L. Theriault. "Special Clinical Situations in Patients with Breast Cancer." In Breast Cancer, 406–29. New York, NY: Springer New York, 2001. http://dx.doi.org/10.1007/978-0-387-21842-7_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Baines, Joanna. "Three Stories: Generations of Breast Cancer." In Cancer Patients, Cancer Pathways, 13–35. London: Palgrave Macmillan UK, 2012. http://dx.doi.org/10.1057/9781137272089_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Petralia, Giuseppe, and Anwar R. Padhani. "One-Step Systemic Staging for Patients with Breast Cancer." In Breast Cancer, 265–76. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48848-6_20.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Vila, Jose, Francisco Ripoll, and Oreste D. Gentilini. "Surgical Treatment of Local Recurrence in Breast Cancer Patients." In Breast Cancer, 349–56. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48848-6_25.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Lambertini, Matteo, Hatem A. Azim, and Fedro A. Peccatori. "Fertility Issues in Patients with Breast Cancer or Survivors." In Breast Cancer, 729–37. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48848-6_61.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Breast Cancer Patients Malaysia"

1

Velaiutham, S. "Tumour associated antigen CA 15-3 in primary breast cancer patients in Malaysia: Correlation with clinical stage and tumour size." In Asian Breast Diseases Association (ABDA) 3rd Teaching Course: Advances in the Management of Breast Diseases. Kuantan, Malaysia: Asian Breast Diseases Association, 2005. http://dx.doi.org/10.2349/biij.1.1.e6-37.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Ng, Patsy P., Wei Xiong Wen, Eldarina Wijaya, Jamie Allen, Joanna Lim, Shao Yan Lau, Brennan Decker, et al. "Abstract 1420: Prevalence ofPALB2mutations in an unselected cohort of breast cancer patients and unaffected individuals from Malaysia and Singapore." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1420.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Wen, Wei Xiong, Kah Nyin Lai, Jamie Allen, Craig Luccarini, Shivaani Mariapun, Cheng Har Yip, Nur Aishah Mohd Taib, Alison Dunning, Douglas Easton, and Soo Hwang Teo. "Abstract 4288: Inherited mutations inBRCA1andBRCA2in an unselected multi-ethnic cohort of Asian breast cancer patients and healthy controls from Malaysia." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4288.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Phuah, Sze-Yee, Lai Meng Looi, Anthony Rhodes, Sarah Dean, Nur Aishah Mohd Taib, Cheng Har Yip, and Soo-Hwang Teo. "Abstract 2609: Addition of ER and PTEN, but not cytokeratins, aids identification for BRCA1 carriers in Malaysian breast cancer patients." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2609.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Jabir, Rafid Salim, Gwo Fuang Ho, Muhammad Azrif bin Ahmad Annuar, and Johnson Stanslas. "Abstract A210: Single nucleotide polymorphisms of ABCB1, SLCO1B3, and CYP3A5: Potential biomarkers of docetaxel adverse effects in Malaysian breast cancer patients." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a210.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Omar Hasan Kasule, SR. "Epidemiology of breast cancer in Malaysia." In Asian Breast Diseases Association (ABDA) 3rd Teaching Course: Advances in the Management of Breast Diseases. Kuantan, Malaysia: Asian Breast Diseases Association, 2005. http://dx.doi.org/10.2349/biij.1.1.e6-14.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Marker, Katie M., Tatiana Vidaurre, Jeannie Navarro Vasquez, Valentina Zavala, Silvia Serrano Gomez, Lizeth Tamayo, Renzo Meza Florez, et al. "Abstract 1589: Breast cancer subtype GWAS in Peruvian breast cancer patients." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1589.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Marker, Katie M., Tatiana Vidaurre, Jeannie Navarro Vasquez, Valentina Zavala, Silvia Serrano Gomez, Lizeth Tamayo, Renzo Meza Florez, et al. "Abstract 1589: Breast cancer subtype GWAS in Peruvian breast cancer patients." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1589.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Rocha, Marina E., Daniel Jesus, Ludiayne M. do Carmo, Lorrany L. Rodrigues, Michelle R. Oliveira, Tatiana F. Silva, Verônica S. Silva, and Lorena T. Quirino. "NURSING ASSISTANCE TO PATIENTS WITH BREAST CANCER." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1ep55.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Carrijo, Sarah B. D., Beatriz A. Negraes, Lucas F. S. Pereira, Larissa F. Almeida, Jordana M. Oliveira, and Cláudio C. S. Medrado. "PATIENTS WITH BREAST CANCER: CHANGES IN BODY IMAGE." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1ep19.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Breast Cancer Patients Malaysia"

1

Novinger, Leah. Identification of Autoantibodies to Breast Cancer Antigens in Breast Cancer Patients. Fort Belvoir, VA: Defense Technical Information Center, October 2011. http://dx.doi.org/10.21236/ada555908.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Schnall, Mitchell D. MRI-Based Screen for Breast Cancer Patients Carrying a Breast Cancer Susceptibility Gene. Fort Belvoir, VA: Defense Technical Information Center, October 1997. http://dx.doi.org/10.21236/ada338681.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Schnall, Michael D. MRI-Based Screen for Breast Cancer Patients Carrying a Breast Cancer Susceptibility Gene. Fort Belvoir, VA: Defense Technical Information Center, October 1998. http://dx.doi.org/10.21236/ada359858.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Schnall, Mitchell D. MRI-Based Screen for Breast Cancer Patients Carrying a Breast Cancer Susceptibility Gene. Fort Belvoir, VA: Defense Technical Information Center, October 1999. http://dx.doi.org/10.21236/ada390928.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Farria, Dione M. Education and Outreach for Breast Imaging and Breast Cancer Patients. Fort Belvoir, VA: Defense Technical Information Center, July 2002. http://dx.doi.org/10.21236/ada407789.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Farria, Dione M. Education and Outreach for Breast Imaging and Breast Cancer Patients. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada420124.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Backonja, Miroslav. Pain Management Skills for Minority Breast Cancer Patients. Fort Belvoir, VA: Defense Technical Information Center, October 2002. http://dx.doi.org/10.21236/ada420284.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Schnall, Mitchell D. MRI-Based Screen for Breast Cancer Patients Carrying a Breast Susceptibility Gene. Fort Belvoir, VA: Defense Technical Information Center, July 2001. http://dx.doi.org/10.21236/ada398696.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Hayes-Bautista, David E. Latina Breast Cancer Patients and Their Informal Support System. Fort Belvoir, VA: Defense Technical Information Center, September 2001. http://dx.doi.org/10.21236/ada403314.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Hayes-Bautista, David E. Latina Breast Cancer Patients and Their Informal Support System. Fort Belvoir, VA: Defense Technical Information Center, September 2002. http://dx.doi.org/10.21236/ada413703.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Breast Cancer Patients Malaysia" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії